VEGFR inhibitor

DRUG CLASS:

VEGFR inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1
KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2

VEGFR inhibitor

VEGFR inhibitor

Associations(336)

Associations
(336)